BioCentury
ARTICLE | Clinical News

Sarilumab: Completed Phase II/III enrollment

November 5, 2012 8:00 AM UTC

The partners disclosed in their 3Q12 earnings that they completed enrollment of 1,197 patients with moderate to severe active RA who had an inadequate response to methotrexate in the double-blind, int...